BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
47 hedge funds and large institutions have $2.19M invested in BRAINSTORM CELL THERAPUTC in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 6 closing their positions.
6,500% more call options, than puts
Call options by funds: $66K | Put options by funds: $1K
111% more capital invested
Capital invested by funds: $1.04M → $2.19M (+$1.15M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 46 → 47 (+1)
0.01% more ownership
Funds ownership: 0.54% → 0.55% (+0.01%)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$40.8K |
| 2 |
KWA
Kingswood Wealth Advisors
San Diego,
California
|
+$29.7K |
| 3 |
BlackRock
New York
|
+$8.42K |
| 4 |
Jane Street
New York
|
+$6.87K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$2.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$19K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.18K |
| 3 |
Barclays
London,
United Kingdom
|
-$6.31K |
| 4 |
ZIG
Zullo Investment Group
Scranton,
Pennsylvania
|
-$4.4K |
| 5 |
Morgan Stanley
New York
|
-$4.16K |
BCLI Hedge Fund Activity: Q1 2024 in Review
47 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2024, worth a combined $2.19M — up 111% from $1.04M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 6 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $40.8K. The largest seller was Virtu Financial, exiting entirely with an estimated $19K sold.
- 47 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2024, up from 46 in Q4 2023.
- Funds reported $2.19M of BRAINSTORM CELL THERAPUTC stock for Q1 2024, up 111% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2024 and 6 closed out, a net change of +1 holder.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2024 was GSA Capital Partners, an estimated $40.8K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2024 was Virtu Financial, an estimated $19K sold.
Based on aggregated 13F filings for Q1 2024.